BioXcel Therapeutics (BTAI)
Develops neuroscience therapies through a data-driven drug re-innovation model.
Something off on this page? Send us feedback.
Uses a drug re-innovation model built on existing approved drugs or clinically validated candidates, big data, and proprietary machine-learning algorithms. The current pipeline includes FDA-approved IGALMI for acute agitation associated with schizophrenia or bipolar I or II in adults, BXCL501 for additional uses, and OnkosXcel’s investigational BXCL701.
Applies a drug re-innovation model to neuroscience, combining existing approved drugs or clinically validated candidates with big data and proprietary machine-learning algorithms to identify therapeutic indications.
IGALMI, a dexmedetomidine sublingual film, is FDA approved for acute agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is the most advanced neuroscience clinical asset for additional uses, while wholly owned OnkosXcel develops investigational immuno-oncology candidate BXCL701.
A reprioritization directed focus toward agitation-market opportunities and reduced institutional IGALMI commercialization expense. Program progress remains subject to clinical and regulatory review; the company has disclosed dependence on additional financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.8M · Total debt $104.5M · Total assets $28.8M · Shareholders' equity −$115.5M
- Revenue
- $182.0K
- Operating income
- −$10.2M
- Net income
- −$14.7M
No dividends on record.
| Institutions | 19.73% | 6.18M shares | |
|---|---|---|---|
| 48 holders · as of Jun 30, 2026 | |||
| Insiders | 0.85% | 266.3K shares | |
| 8 holders · as of Jun 17, 2026 | |||
| Strategic holders | 8.29% | 2.60M shares | |
| 3 holders · as of May 15, 2026 | |||
| Other | 71.13% | 22.27M shares | |
| remainder | |||
31.31M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Millennium Management LLCInstitution | 6.76% | 2.11M | as of Jun 30, 2026 |
Armistice Capital, LLCStrategic | 6.10% | 1.91M | filed May 15, 2026 |
Oaktree Capital Management LPInstitution | 4.41% | 1.38M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.94% | 919,545 | as of Jun 30, 2026 |
BioXcel LLC1,2Strategic10 percent owner | 1.90% | 594,040 | filed Sep 28, 2023 |
- BioXcel LLC's transaction reports restate only vehicles that traded; the 2023 ownership statement (594.0K) is used instead.
- BioXcel LLC reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Vimal Mehta | director, officer: CEO and President | −19,419 | $1.09 |
| May 20, 2026 | Richard I. Steinhart | officer: Chief Financial Officer | −6,845 | $1.09 |
| May 20, 2026 | Javier Rodriguez | officer: See Remarks | −6,560 | $1.08 |
| May 20, 2026 | Frank Yocca | officer: Chief Scientific Officer | −6,845 | $1.09 |
- Eli Lilly
Intramuscular option for acute agitation in schizophrenia and bipolar I
- Pfizer
Intramuscular treatment for acute agitation in schizophrenia
- Neumora Therapeutics
Clinical Alzheimer's-agitation program using a V1a receptor antagonist
- AbbVie
Oral treatment coverage in schizophrenia and bipolar I mania
- Bristol-Myers Squibb
Oral M1/M4 treatment for adult schizophrenia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics | $0.0739 | 0.00% | $2.3M | — | — | 3.1 | +51.7% |
| Eli Lilly | $1,152.13 | −1.54% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Pfizer | $27.92 | −0.04% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Neumora Therapeutics | $0.7306 | −6.15% | $144.2M | — | — | — | — |
| AbbVie | $264.77 | −0.17% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Bristol-Myers Squibb | $61.24 | −1.62% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Median | 38.1 | 13.7 | 4.9 | +8.0% |